AstraZeneca’s trastuzumab deruxtecan therapy has received official approval from India’s Central Drugs Standard Control Organization (CDSCO). This approval allows the drug to be used in the treatment of HER2-low and very-low breast cancer in adult patients.
Monotherapy for Unresectable or Metastatic Breast Cancer
Trastuzumab deruxtecan has now been approved as a monotherapy for adults with unresectable or metastatic breast cancer in India. This means patients with HER2-low and very-low breast cancer who cannot undergo surgery or have advanced-stage cancer can now access this targeted treatment.
Expanding Treatment Options
The CDSCO approval marks a significant step in expanding the availability of trastuzumab deruxtecan for a specific group of breast cancer patients in India. The therapy offers a new option for those with limited treatment choices, potentially improving outcomes for this patient population.
Related topics:
- A Guide To Breast Augmentation Surgery Side Effect Categories
- 5 Easy Ways To Ease Tender Breast Pain
- 6 Different Types Of Fake Breasts
